Can-Fite BioPharma Ltd. (nyse mkt:CANF) (tase:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced that the U.S. FDA has agreed with the Company’s study protocol for its Phase II clinical trial of CF102 for the treatment of advanced liver cancer. The FDA has granted Can-Fite Orphan Drug designation for CF102 in this indication.Can Fite Biopharma Ltd (ADR) (NYSEMKT:CANF) weekly performance is -0.50%. Analysts mean target price for the company is $28.00. Can Fite Biopharma Ltd (ADR) (NYSEMKT:CANF) distance from 50-day simple moving average is -20.83%.
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, has added additional office space at 379 Thornall Street, Edison, NJ. The Company will continue to maintain its corporate headquarters in New York City.Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) shares advanced 1.97% in last trading session and ended the day on $12.40. ATNM its return on assets is -228.60%. Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) quarterly performance is 125.45%.
The Puma Biotechnology Inc (NYSE:PBYI) on June 1 announced the presentation of positive results from an ongoing Phase II clinical trial of Puma’s investigational drug PB272 (neratinib) for the treatment of HER2 positive metastatic breast cancer that has metastasized to the brain. The data was presented in a poster presentation at the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting in Chicago, Illinois. The multicenter Phase II clinical trial is enrolling patients with HER2 positive metastatic breast cancer who have brain metastases. Puma Biotechnology Inc (NYSE:PBYI) shares moved down -25.34% in last trading session and was closed at $57.06, while trading in range of $56.06-$65.79. Puma Biotechnology Inc (NYSE:PBYI) year to date performance is -44.89%.
Stock analysts at Canaccord Genuity began coverage on shares of Lannett Company (NYSE:LCI) in a report issued on Tuesday.The firm set a “buy” rating and a $55.00 price target on the stock. Lannett Company, Inc. (NYSE:LCI) ended the last trading day at $42.16. Company weekly volatility is calculated as 3.57% and price to cash ratio as 12.14. Lannett Company, Inc. (NYSE:LCI) showed a positive weekly performance of 10.42%.
GTX, Inc. (NASDAQ:GTXI) announced positive results from a Phase 2, proof-of-concept, open-label clinical study evaluating enobosarm (GTx-024), a selective androgen receptor modulator (SARM), for the treatment of patients with androgen receptor (AR) positive and estrogen receptor (ER) positive metastatic breast cancer who have previously responded to hormonal therapy.GTx, Inc. (NASDAQ:GTXI) weekly performance is 3.65%. On last trading day company shares ended up $1.42. Analysts mean target price for the company is $1.50. GTx, Inc. (NASDAQ:GTXI) distance from 50-day simple moving average is -3.68%.